Life Sciences Ophthalmology Devices & Therapeutics sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Life Sciences Ophthalmology Devices & Therapeutics
1.1 - About Life Sciences Ophthalmology Devices & Therapeutics sector
Companies in Life Sciences Ophthalmology Devices & Therapeutics develop and commercialize treatments, implants, surgical systems, and diagnostic imaging for eye diseases and vision correction. Their offerings enable ophthalmologists and optometrists to detect pathology earlier, perform precise procedures, and manage chronic conditions like glaucoma, cataracts, retinal disorders, and dry eye. Buyers rely on these vendors for clinically validated products that improve outcomes, streamline workflows, and support practice economics.
These companies typically offer ophthalmic pharmaceuticals for retina and glaucoma, phacoemulsification and femtosecond laser systems for cataract surgery, vitrectomy platforms for posterior segment procedures, and a full range of intraocular lenses with advanced optics. They provide OCT and fundus imaging, corneal topography and biometry devices, AI-enabled screening and image analysis software, as well as sustained-release drug delivery implants and surgical consumables such as viscoelastics and microsurgical instruments.
They serve hospital ophthalmology departments, ambulatory surgery centers, and independent eye care clinics. Outcomes include earlier disease detection, higher surgical precision, reduced complications, and faster patient throughput. Customers also see improved chronic disease management, better visual acuity results, and stronger reimbursement and quality metrics, making these vendors attractive strategic buyers in ophthalmology-focused life sciences.
2. Buyers in the Life Sciences Ophthalmology Devices & Therapeutics sector
2.1 Top strategic acquirers of Life Sciences Ophthalmology Devices & Therapeutics companies
4D Molecular Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage genetic medicine therapies built on a proprietary Therapeutic Vector Evolution platform that creates customized AAV vectors and supports a diverse pipeline of gene therapy candidates aimed at treating large-market and rare diseases.
- Key Products:
- Therapeutic Vector Evolution platform: Combines directed evolution with ~1 billion synthetic capsid sequences to engineer AAV vectors that efficiently transduce target tissues while reducing immunogenicity
- 4D-125: A Phase 1/2 gene therapy candidate employing evolved AAV vectors to treat X-linked retinitis pigmentosa by delivering therapeutic genes via routine, minimally invasive ocular administration
- 4D-110: Phase 1 gene therapy designed for choroideremia, using targeted AAV capsids to reach diseased retinal cells and correct underlying genetic defects
- 4D-310: Phase 1/2 gene therapy for Fabry disease that delivers corrective genes to cardiac tissue through evolved vectors intended to overcome pre-existing antibodies and improve cardiac function.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Life Sciences Ophthalmology Devices & Therapeutics sector
M&A buyer group 1: Ophthalmological Gene Therapy
5 companies
View group →
Description: Companies in Life Sciences Ophthalmic Gene Therapies research, develop, and commercialize genetic medicines targeting retinal and other ocular diseases. They engineer viral vectors and delivery methods tailored to the eye, advance candidates through preclinical and clinical stages, and partner for manufacturing and distribution. Their value proposition is restoring or preserving vision with durable, one-time treatments and de-risked development programs aligned with regulatory pathways.
Kriya Therapeutics
- Type: N/A
- Employees: ●●●●●
- Description: Provider of single-dose adeno-associated virus (AAV) gene therapies developing treatments for chronic diseases, including geographic atrophy, trigeminal neuralgia, thyroid eye disease, focal epilepsy, type 1 diabetes and metabolic dysfunction-associated steatohepatitis (MASH).
- Key Products:
- KRIYA-497 AAV-FGF21 Gene Therapy: Investigational intramuscular gene therapy that reverses hepatic fibrosis and halts liver tumor development in preclinical MASH models, offering durable disease modification
- Kriya-839 Gene Therapy: Potential single-administration gene therapy designed to transform management of type 1 diabetes by providing long-term glycemic control and reducing treatment burden
- Gene Therapy Manufacturing Platform: Integrated core technology and manufacturing capabilities enabling scalable production and commercialization of diverse AAV-based therapies with improved accessibility for patients
- Multidisease Gene Therapy Pipeline: Portfolio of clinical and preclinical programs targeting ophthalmology, metabolic disease and neurology indications, supported by ongoing research and thirteen presented abstracts.
🔒
🔒
🔒
View all 5 companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms in Life Sciences Ophthalmology Devices & Therapeutics sector
3.1 - Buyout funds in the Life Sciences Ophthalmology Devices & Therapeutics sector
2.2 - Strategic buyer groups for Life Sciences Ophthalmology Devices & Therapeutics sector
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Life Sciences Ophthalmology Devices & Therapeutics companies
4.2 - Public trading comparable groups for Life Sciences Ophthalmology Devices & Therapeutics sector
Valuation benchmark group 1: Surgical Systems and Devices Manufacturers
27 companies
View group →
Description: Companies in this public trading comparables group design, manufacture, and market surgical systems and interventional medical devices across ophthalmology, orthopedics, cardiology, endoscopy, radiation oncology, and robotic-assisted surgery. They sell capital equipment supported by high-margin consumables and service contracts, enabling recurring revenue. Grouped for valuation benchmarks, these device makers share similar regulatory pathways, provider-focused commercial models, and procedure-driven demand profiles that underpin comparable growth and margin dynamics.
Intuitive Surgical
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of robotic-assisted surgical systems and related instruments that enhance the ability of doctors to perform complex surgeries using minimally invasive techniques. Develops, manufactures, and markets the da Vinci Surgical System, offering improved clinical outcomes and greater access to definitive care.
- Key Products:
- da Vinci Surgical System: Robotic-assisted platform that enhances surgeons’ capabilities in performing complex procedures
- EndoWrist Instruments: Surgical instruments designed for use with the da Vinci Surgical System
- E-200 Generator: High-frequency energy generator for cutting, coagulation, and rapid vessel sealing
- Firefly Imaging System: Advanced imaging technology for enhanced visualization during surgery
- Training Programs: Comprehensive training and education services for healthcare providers
🔒
🔒
🔒
View all 27 companies in this group
Request Free Trial Now →
🔒
Revenue growth
Median
15.7%
2025E
16.0%
2026E
EBITDA margin
Median
28.2%
2025E
28.6%
2026E
Cash EBITDA margin
Median
27.6%
2025E
28.0%
2026E
EV/Revenue
Median
8.4x
2025E
6.8x
2026E
EV/EBITDA
Median
28.9x
2025E
24.4x
2026E
EV/Cash EBITDA
Median
29.0x
2025E
25.5x
2026E
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →